Current Prognostic models for overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) have become dated. They don’t adequately reflect the many new drugs used in clinical practice. To develop a relevant model data from a phase III trial of 1,050 men with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance]) was evaluated. [...]
The PSA controversy continues to plague men’s health. The United States Preventive Task Force’s recommendation against using the PSA blood test as a screening tool for prostate cancer (PCa) will bring additional harms to men. Since the beginning of PSA testing the mortality rate from prostate cancer has declined significantly, but there has been no [...]
Today’s post will be a little admonishment of you, my loyal readers. So, please be open-minded and think about what I have to say to you. A number of months ago I mentioned the new prostate cancer research-funding project we have embarked upon, Start A Cure (www.StartACure.com). For those of you who might have missed [...]
Dr. Nima Sharifi from the Cleveland Clinic’s Lerner Research Institute has claimed to have identified a genetic mutation in one of the deadliest forms of prostate cancer. His finding, published online today in the journal Cell, shows that there is a mutation that occurs in an enzyme that is present in a drug resistant form [...]
A few days ago I wrote about Malecare’s new program addition, Start A Cure in my post “Announcing A New Research Platform – Start A Cure.” The program goal is to raise funding for cancer research by allowing each of us, as individuals, to pick the projects we want to fund and then to make [...]